Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844273 | 0.90 | EDNRA (0.35) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL4838098 | 0.84 | KDM4E (0.37) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL3137401 | 0.84 | ALDH1A1 (0.34) | MEN1KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4838426 | 0.82 | PDE4A (0.32) | — | |
| SCHEMBL4415057 | 0.81 | SLC29A1 (0.30) | — | |
| SCHEMBL4838306 | 0.81 | PDE4A (0.32) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL4838681 | 0.80 | ABL1 (0.34) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL4838731 | 0.79 | PKM (0.34) | MEN1KMT2ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4845137 | 0.78 | KMT2A (0.37) | MEN1KMT2AKDM4ELMNARAB9A | |
| SCHEMBL4834803 | 0.78 | TSHR (0.33) | MEN1KMT2AKDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7145006-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-12-05 | — | — | US | disclosed |
| US-7125994-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-10-24 | — | — | US | disclosed |
| US-20060008835-A1 | PNA monomer and precursor | KIM SUNG K | 2006-01-12 | — | — | US | disclosed |
| US-20060003374-A1 | Method of making PNA oligomers | KIM SUNG K | 2006-01-05 | — | — | US | disclosed |
| US-20050283005-A1 | PNA monomer and precursor | KIM SUNG K | 2005-12-22 | — | — | US | disclosed |
| US-6969766-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-29 | — | — | US | disclosed |
| US-20050250785-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20050250786-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050283005-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | MEN1 3369/4885KMT2A 4022/4885KDM4E 4849/4885 |
| US-20050250785-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | MEN1 3369/4885KMT2A 4022/4885KDM4E 4849/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | MEN1 3281/4885KMT2A 4071/4885KDM4E 4848/4885 |
| US-20060008835-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | MEN1 3369/4885KMT2A 4022/4885KDM4E 4849/4885 |
| US-20050250786-A1 | PNA monomer and precursor | PNISR, RNGTT, NPR1 | MEN1 3505/4885KMT2A 3823/4885KDM4E 4843/4885 |
| US-20060003374-A1 | Method of making PNA oligomers | RNGTT, POLL, PNISR | MEN1 4168/4885KMT2A 4022/4885KDM4E 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.